What "drives" the link between the renin-angiotensin-aldosterone system and the prothrombotic state in hypertension?
Tay
Kok-Hoon
KH
Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.
Lip
Gregory Y H
GY
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D019317:Evidence-Based Medicine; D005609:Free Radicals / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D009569:Nitric Oxide / Q000096:biosynthesis*; D011516:Prothrombin / Q000187:drug effects / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000187:drug effects; D013927:Thrombosis / Q000503:physiopathology / Q000517:prevention & control
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D005609:Free Radicals; D009569:Nitric Oxide; D011516:Prothrombin